Back to results
US 12,297,218 B2Granted
Complex comprising a PSMA-targeting compound linked to a lead or thorium radionuclide
AssigneeSciencons AS
InventorRoy Hartvig Larsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to complexes comprising a prostate-specific membrane antigen (PSMA) targeting compound linked to a radionuclide, such as 212Pb or 227Th, through a TCMC or DOTA chelating moiety. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.
Claims20
A complex comprising:
- a) a compound having the formula of
- or a pharmaceutically acceptable salt thereof,
- wherein,
- Z is p-SCN-Bn-TCMC;
- and
- b) a radionuclide complexed with the TCMC, wherein the radionuclide is 212Pb.
3 more elements
Dependencies are inferred from the claim text.